Pharmacodynamics of orally administered sustained- release hydromorphone in humans.
about
Mouse current vocalization threshold measured with a neurospecific nociception assay: the effect of sex, morphine, and isofluraneA randomized, double-blind comparison of OROS(R) hydromorphone and controlled-release morphine for the control of chronic cancer pain.Laser-evoked potentials as a tool for assessing the efficacy of antinociceptive drugs.An open-label, 1-year extension study of the long-term safety and efficacy of once-daily OROS(R) hydromorphone in patients with chronic cancer pain.Metabolic activation and analgesic effect of flupirtine in healthy subjects, influence of the polymorphic NAT2, UGT1A1 and GSTP1.A prospective multicentre study to evaluate the efficacy and tolerability of osmotic release oral system (OROS) hydromorphone in opioid-naive cancer patients: Results of the Korean South West Oncology Group studyRepeat-dose steady-state pharmacokinetic evaluation of once-daily hydromorphone extended-release (OROS(®) hydromorphone ER) in patients with chronic painEpigenetic regulation of opioid-induced hyperalgesia, dependence, and tolerance in mice.The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusers.A comparison of long- and short-acting opioids for the treatment of chronic noncancer pain: tailoring therapy to meet patient needsComplementary pharmacokinetic measures to further define the profile of once-daily OROS hydromorphone ER during single-dose and steady-state dosing.Once-Daily OROS Hydromorphone for Management of Cancer Pain: an Open-Label, Multi-Center, Non-Interventional Study.Primary care considerations of the pharmacokinetics and clinical use of extended-release opioids in treating patients with chronic noncancer pain.Assessment of extended-release opioid analgesics for the treatment of chronic pain.Opioid pharmacogenomics using a twin study paradigm: methods and procedures for determining familial aggregation and heritability.Opioid Pharmacokinetics-Pharmacodynamics: Clinical Implications in Acute Pain Management in Trauma.Hydromorphone for cancer pain.A new extended release formulation (OROS) of hydromorphone in the management of pain.The sensitization of a broad spectrum of sensory nerve fibers in a rat model of acute postoperative pain and its response to intrathecal pharmacotherapy.Peripheral opioid analgesia in experimental human pain models.Cytochrome P450 epoxygenase dependence of opioid analgesia: fluconazole does not interfere with remifentanil-mediated analgesia in human subjects.Single-dose evaluation of safety, tolerability and pharmacokinetics of newly formulated hydromorphone immediate-release and hydrophilic matrix extended-release tablets in healthy Japanese subjects without co-administration of an opioid antagonist.Use of OROS® hydromorphone in the treatment of osteoarthritis and osteoporosis: A pooled analysis of three non-interventional studies focusing on different starting doses.A randomized study of the effects of food on the pharmacokinetics of once-daily extended-release hydromorphone in healthy volunteers.
P2860
Q30462485-1B8542EC-E494-4E99-9181-297C689FB702Q33381853-D82599A0-719D-4CEB-9523-761C69004675Q33455120-00F0AA12-9BF1-4358-AE47-06CB6E108491Q33503399-D8D8CE3F-5759-4AAB-B177-D0596F09FB1EQ35135974-44FA5B3E-7C33-433A-8B83-419B9499E2D1Q36365111-93E96AB1-FBFB-4A01-9DE3-E0028D4B0AB8Q36407485-8DF1A38A-2AA2-465F-8C64-2EEEDA6F9FCAQ36516966-99BB4FCF-CC93-4FD7-9770-26753F537D40Q37156564-92B53C05-AEFD-4D3B-9C6A-A23AB590F5CEQ37246245-4B9A488C-E7B9-4DD3-B751-93519D1A19FCQ37392741-BD4D7BA3-056A-4693-966B-009491BCFED6Q37404917-E69CB5E1-9979-4735-8D09-E1D795FB844AQ38079923-690F3C9C-5CC6-48BA-A18D-4A6540ADF1E6Q38092855-D949F392-FADE-46B7-8C56-BC25BD0088E3Q38427278-8714EC8D-F367-4B2D-B886-1DD1453B677AQ38688819-4A51A5AC-9B0D-4275-B5B8-3EEC2582F6C4Q38977999-91D720FD-10B3-4055-8148-2A20F4477FA0Q41436187-59B0734F-0385-4D17-8CD5-B7098F391808Q42151072-D638F327-EEEF-4BB1-B391-FF804B90609DQ44341140-83A4BB1E-0513-4D32-B946-669FADE53E08Q44346631-9A8FBCB5-1228-40DB-9219-7E9A63036C02Q44350287-82D4524E-9103-45D0-A605-71EEE9D7FEEAQ46230761-C247A6C4-1139-4F04-AFE2-95B4EF0D6D17Q51386305-56C53181-663E-4575-A1EB-B39ADC591553
P2860
Pharmacodynamics of orally administered sustained- release hydromorphone in humans.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Pharmacodynamics of orally administered sustained- release hydromorphone in humans.
@ast
Pharmacodynamics of orally administered sustained- release hydromorphone in humans.
@en
type
label
Pharmacodynamics of orally administered sustained- release hydromorphone in humans.
@ast
Pharmacodynamics of orally administered sustained- release hydromorphone in humans.
@en
prefLabel
Pharmacodynamics of orally administered sustained- release hydromorphone in humans.
@ast
Pharmacodynamics of orally administered sustained- release hydromorphone in humans.
@en
P2093
P1433
P1476
Pharmacodynamics of orally administered sustained- release hydromorphone in humans.
@en
P2093
Ramaswamy B
Stanski DR
P356
10.1097/00000542-200101000-00014
P407
P577
2001-01-01T00:00:00Z